| Pitavastatin (usually as a calcium salt) is a member of the blood cholesterol lowering medication class of statins.
Pitavastatin is an inhibitor of HMG-CoA reductase, the enzyme that catalyses the first step of cholesterol synthesis.
It was patented in 1987 and approved for medical use in 2003. It is available in Japan, South Korea and in India. In the US, it received FDA approval in 2009.
Kowa Pharmaceuticals, a subsidiary of Kowa Company, is the owner of the American patent to pitavastatin. |
|
Read full article at Wikipedia
|
InChI=1S/C33H35FN2O5/c1- 21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1 |
| XUKUURHRXDUEBC-KAYWLYCHSA-N |
| CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1 |
|
|
environmental contaminant
Any minor or unwanted substance introduced into the environment that can have undesired effects.
Bronsted acid
A molecular entity capable of donating a hydron to an acceptor (Bronsted base).
(via oxoacid )
|
|
|
xenobiotic
A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor
Any EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD+ or NADP+ acceptor) inhibitor that inhibits HMG-CoA reductases. Hydroxymethylglutaryl-CoA reductase inhibitors have been shown to lower directly cholesterol synthesis. The Enzyme Commission designation is EC 1.1.1.34 for the NADPH-dependent enzyme and EC 1.1.1.88 for an NADH-dependent enzyme.
(via statin )
|
|
|
anticholesteremic drug
A substance used to lower plasma cholesterol levels.
(via statin )
|
|
View more via ChEBI Ontology
|
(3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
|
|
atorvastatin
|
ChemIDplus
|
atorvastatina
|
ChEBI
|
atorvastatine
|
ChEBI
|
atorvastatinum
|
ChEBI
|
|
(R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
|
ChemIDplus
|
|
7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID
|
PDBeChem
|
|
Atorvastatin
|
KEGG COMPOUND
|
|
Atorlip
|
ChEBI
|
Atorpic
|
DrugBank
|
|
Liprimar
|
DrugBank
|
|
117
|
PDBeChem
|
|
257
|
DrugCentral
|
|
Atorvastatin
|
Wikipedia
|
|
C06834
|
KEGG COMPOUND
|
|
D07474
|
KEGG DRUG
|
|
DB01076
|
DrugBank
|
|
EP409281
|
Patent
|
|
HMDB0005006
|
HMDB
|
|
LSM-5771
|
LINCS
|
|
US5273995
|
Patent
|
| View more database links |
|
134523-00-5
|
CAS Registry Number
|
ChemIDplus
|
|
8373630
|
Beilstein Registry Number
|
Beilstein
|
|
8373630
|
Reaxys Registry Number
|
Reaxys
|
|
2014-10-29
